Haverford Trust Co Raises Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Haverford Trust Co increased its holdings in Thermo Fisher Scientific Inc. by 5.4% in Q1, owning approximately 220,235 shares valued at $109.59 million.
• Several institutional investors have made new purchases in Thermo Fisher, contributing to a total institutional ownership of 89.23% of the company's stock.
• Analysts have set an average price target of $593.00 for Thermo Fisher stock, with most providing a "Buy" or "Outperform" rating.

Haverford Trust Co grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 220,235 shares of the medical research company's stock after purchasing an additional 11,275 shares during the period. Haverford Trust Co owned approximately 0.06% of Thermo Fisher Scientific worth $109,589,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $25,000. Ameriflex Group Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at about $31,000. IMA Advisory Services Inc. bought a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $35,000. Finally, Navigoe LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on TMO. UBS Group increased their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Argus lowered their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Barclays increased their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a report on Thursday, July 24th. Finally, Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Stock Up 3.4%

Shares of NYSE TMO opened at $500.2380 on Friday. The firm has a 50-day simple moving average of $443.02 and a two-hundred day simple moving average of $457.46. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a market cap of $188.89 billion, a P/E ratio of 28.93, a PEG ratio of 2.58 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the firm posted $5.37 earnings per share. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 295 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total transaction of $147,511.80. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,591,606.96. This represents a 0.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,896 shares of company stock valued at $8,593,838 in the last ninety days. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.